润达医疗(603108) - 2023 Q1 - 季度财报

Financial Performance - The operating revenue for the first quarter of 2023 was CNY 2,178,109,255.75, representing a year-on-year increase of 0.44%[3] - The net profit attributable to shareholders of the listed company was CNY 81,035,808.45, a significant increase of 96.09% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 72,308,631.48, reflecting a growth of 94.56% year-on-year[3] - The basic earnings per share for the period was CNY 0.14, which is an increase of 96.33% compared to the previous year[4] - The diluted earnings per share also stood at CNY 0.14, marking a 96.33% increase year-on-year[4] - The total comprehensive income attributable to the parent company reached CNY 81,582,592.00, a significant increase from CNY 40,804,562.03 in the same quarter last year, representing a growth of 100.5%[27] - Net profit for Q1 2023 was CNY 119,347,203.83, up from CNY 79,878,924.73 in Q1 2022, reflecting an increase of approximately 49.5%[46] - The net profit attributable to shareholders of the parent company was CNY 81,035,808.45 in Q1 2023, compared to CNY 41,325,857.98 in Q1 2022, indicating a growth of around 96.4%[46] - The net profit for the first quarter of 2023 was CNY 64,806,486.79, a significant increase compared to CNY 13,152,659.21 in the same period last year, representing a growth of approximately 392%[53] - The total profit amounted to CNY 64,244,797.32, compared to a loss of CNY 912,548.57 in the previous year, indicating a turnaround in profitability[53] Cash Flow - The net cash flow from operating activities was negative at CNY -129,971,560.02, a decline of 61.10% compared to the same period last year[4] - The net cash flow from operating activities increased by 61.10%, amounting to 204 million RMB, primarily due to increased cash receipts from sales[18] - The net cash flow from operating activities was CNY 113,588,159.56, compared to CNY 78,591,481.24 in the first quarter of 2022, indicating an increase of 44.5%[34] - The cash inflow from financing activities was CNY 1,513,918,178.18, significantly higher than CNY 890,999,983.04 in the first quarter of 2022, marking an increase of 69.8%[34] - The cash inflow from financing activities increased to CNY 2,613,452,131.77 in Q1 2023, compared to CNY 1,947,844,773.11 in Q1 2022, marking an increase of approximately 34.2%[48] - The net increase in cash and cash equivalents for the quarter was CNY 24,624,381.04, contrasting with a decrease of CNY 85,515,434.89 in the same period last year[34] - The company's cash and cash equivalents at the end of Q1 2023 were CNY 466,206,613.92, slightly down from CNY 470,204,234.54 at the end of Q1 2022[49] Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 14,673,621,310.60, up 1.07% from the end of the previous year[4] - The total assets of the company reached 14.674 billion RMB, an increase from 14.519 billion RMB in the previous period[12] - The total liabilities amounted to 9.576 billion RMB, compared to 9.509 billion RMB in the previous period[24] - The total assets increased to CNY 8,373,299,091.77, compared to CNY 8,068,429,488.83 in the previous year, reflecting a growth of 3.8%[52] - The total liabilities increased to CNY 5,763,774,778.24, compared to 5,523,731,373.89 in the previous year, indicating a rise of 4.4%[52] Operational Efficiency - The weighted average return on net assets was 2.06%, an increase of 0.87 percentage points compared to the end of the previous year[4] - The company's inventory decreased to 1.525 billion RMB from 1.616 billion RMB, indicating a reduction of approximately 5.66%[12] - The company reported a decrease in accounts receivable to 5.899 billion RMB from 5.921 billion RMB, a reduction of approximately 0.37%[12] - The company's long-term equity investments rose to CNY 4,490,838,324.42, compared to CNY 4,334,379,169.64 in the previous year, reflecting a growth of 3.6%[51] - The company's short-term borrowings increased to CNY 1,630,577,340.06 from CNY 1,589,300,133.83 in the previous year[51] Research and Development - Research and development expenses rose to CNY 32,638,835.84 in Q1 2023 from CNY 31,421,115.22 in Q1 2022, an increase of about 3.9%[44] Other Financial Metrics - The company reported non-recurring gains and losses totaling CNY 8,727,176.97 for the period[7] - The company reported a credit impairment loss of CNY 3,804,309.85, compared to a loss of CNY 4,651,822.14 in the previous year, showing an improvement in credit quality[53] - Other comprehensive income after tax for Q1 2023 was CNY 623,631.58, compared to a loss of CNY 594,341.14 in Q1 2022, indicating a positive turnaround[46] - The company did not apply new accounting standards for the first quarter of 2023, which may impact future financial reporting[58]